Overview
Influenza A virus subtype H7N9 is a zoonotic avian influenza strain that can cause severe respiratory illness in humans, primarily transmitted through close contact with infected poultry. 1Diagnosis
Confirmed through RT-PCR testing of nasopharyngeal aspirates.
Close contacts typically test negative for the virus, indicating limited human-to-human transmission risk. 1Management
First-line treatment: Oseltamivir initiation within 48 hours of symptom onset is recommended.
- Severe cases benefit significantly from earlier treatment initiation compared to mild cases (within 2 days vs 4.5 days). 1
Monitor viral shedding duration: Longer shedding duration in severe cases suggests prolonged antiviral therapy may be necessary. 1Special Populations
Elderly and Comorbidities: Severe cases predominantly affect elderly patients and those with underlying health conditions, highlighting the need for vigilant monitoring and early intervention in these groups. 1Key Recommendations
Initiate oseltamivir treatment within 2 days of symptom onset for suspected H7N9 influenza to improve outcomes (Evidence: Moderate) 1
Closely monitor viral shedding duration, especially in severe cases, to guide the duration of antiviral therapy (Evidence: Weak) 1
Prioritize early diagnosis and treatment in elderly patients and those with comorbidities due to higher risk of severe outcomes (Evidence: Expert opinion) 1References
1 Leung YH, To MK, Lam TS, Yau SW, Leung OS, Chuang SK. Epidemiology of human influenza A(H7N9) infection in Hong Kong. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2017. link